WAVE Life Sciences Ltd. (Nasdaq: WVE) is thrilled to announce that their President and Chief Executive Officer, Dr. Paul Bolno, MD, MBA, is scheduled to take part in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023.
With a commitment to delivering life-changing treatments to those who battle devastating diseases, Dr. Bolno is sure to bring a unique perspective to the event. Don’t miss out on this informative and inspiring session!
Don’t miss the opportunity to hear Wave Life Sciences’ newest corporate updates – join us for a live webcast on the Investor Relations page of our website! You can also watch a replay of the presentation for a limited time after the event. Stay tuned for the latest news and insights from Wave Life Sciences.
About Wave Life Sciences
Wave Life Sciences is on a mission to revolutionize the future of gene therapy with its proprietary PRISM platform. As a clinical-stage genetic medicines company, Wave is dedicated to developing life-altering treatments for people suffering from devastating diseases.
Wave’s cutting-edge technologies allow the precise design, optimization, and production of stereopure oligonucleotides to create best-in-class treatments for a broad range of genetic disorders. With a sense of urgency, Wave is committed to improving the lives of patients and their families with the promise of a brighter future.